PAUL ALAN MARKS, MD
Osteopathic Medicine in New York, NY

5700811, Dec 23, 1997

May 19, 1994

8/246363

Ronald Breslow - Englewood NJ
Paul A. Marks - Washington CT
Richard A. Rifkind - New York NY

Sloan-Kettering Institute for Cancer Research - New York NY

H01N 4390, H01N 4342, C07C23300, C07D27704

514314

This invention is directed to compounds having the structure: ##STR1## wherein R. sub. 1 and R. sub. 2 are independently the same as or different from each other; when R. sub. 1 and R. sub. 2 are the same, each is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine or thiazoleamino group; when R. sub. 1 and R. sub. 2 are different, R. sub. 1 =R. sub. 3 --N--R. sub. 4, and n is an integer from about 4 to about 8. This invention also provides a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells. The invention further provides pharmaceutical compositions comprising a therapeutically effective amount of the compounds of the present invention and a pharmaceutically acceptable carrier.

7799803, Sep 21, 2010

Feb 22, 2007

11/710036

Ronald Breslow - Englewood NJ, US
Thomas A. Miller - Brookline MA, US
Sandro Belvedere - New York NY, US
Paul A. Marks - Washington CT, US
Victoria M. Richon - Wellesley MA, US
Richard A. Rifkind - New York NY, US

The Trustees of Columbia University in the City of New York - New York NY
Sloan-Kettering Institute for Cancer Research - New York NY

A61K 31/04, C07D 215/38

514313, 546163

The present invention relates to a novel class of hydroxamic acid derivatives having at least two aryl containing groups, at least one of which is a quinolinyl, isoquinolinyl or benzyl moiety, linked to the hydroxamic acid group through a methylene chain. The hydroxamic acid compounds can be used to treat cancer, for example, brain cancer. The hydroxamic acid compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.

2009005, Feb 26, 2009

Oct 8, 2008

12/287490

George Sgouros - Ellicott City MD, US
Victoria M. Richon - Rye NY, US
Paul A. Marks - Washington CT, US
Richard A. Rifkind - New York NY, US

A61M 36/02, A61P 35/00, A61K 31/167

600 2, 514575

The present invention relates to a method for the treatment of cancer in a patient in need thereof. The method comprises administering to a patient in need thereof a first amount of a histone deacetylase inhibitor in a first treatment procedure, and a second amount or dose of radiation in a second treatment procedure. The first and second treatments together comprise a therapeutically effective amount. The combination of the HDAC inhibitor and radiation therapy is therapeutically synergistic.

2010027, Oct 28, 2010

Jul 2, 2010

12/829740

Nicholas G. Bacopoulos - Stonington CT, US
Judy H. Chiao - Berkeley Heights NJ, US
Paul A. Marks - Washington CT, US
Thomas A. Miller - Brookline MA, US
Carolyn M. Paradise - Cortland Manor NY, US
Victoria M. Richon - Wellesley MA, US
Richard A. Rifkind - New York NY, US

A61K 31/7068, A61P 35/02, A61P 35/00

514 49

The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, in a first treatment procedure, and a second amount of an anti-cancer agent in a second treatment procedure. The first and second amounts together comprise a therapeutically effective amount. The effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.

2005028, Dec 29, 2005

Jun 3, 2005

11/144301

Paul Marks - Washington CT, US
Johanna Ungerstedt - Stockholm, SE

A61K038/00

514012000, 514044000

The invention relates to methods for monitoring patient response to histone deacetylase inhibitors (e.g., suberoylanilide hydroxamic acid (SAHA)) or other therapeutic agents by measuring the level of thioredoxin in body fluids, tissues, and/or cells, such as peripheral blood mononuclear cells, plasma, or serum. The invention also relates to methods of monitoring and/or assisting with the diagnosis of a wide variety of thioredoxin-related diseases and conditions, such as inflammatory diseases, allergic diseases, autoimmune diseases, diseases associated with oxidative stress or diseases characterized by cellular hyperproliferation.

2011012, May 26, 2011

Jan 31, 2011

13/017447

Victoria M. Richon - Wellesley MA, US
Paul A. Marks - Washington CT, US
Richard A. Rifkind - New York NY, US

Sloan-Kettering Institute for Cancer Research - New York NY

A61K 31/167, A61P 35/00

514575

The present application is directed to a method of treating diseases of the central nervous system (CNS) comprising administering to a individual in need of treatment a therapeutically effective amount of an inhibitor of histone deacetylase. In particular embodiments, the CNS disease is a neurodegenerative disease. In further embodiments, the neurogenerative disease is an inherited neurodegenerative disease, such as those inherited neurodegenerative diseases which are polyglutamine expansion diseases. The individual can be a mammal such as a primate or human.

7063973, Jun 20, 2006

Jun 14, 2002

10/173539

Victoria M. Richon - Rye NY, US
Xianbo Zhou - Dobbs Ferry NY, US
Richard A. Rifkind - New York NY, US
Paul A. Marks - Washington CT, US

Sloan-Kettering Institute for Cancer Research - New York ny NY

C12N 9/16, C12N 1/20, C12N 15/00, C07H 21/04

435196, 4352523, 4353201, 536 231, 424 946

The present invention features substantially pure HDAC9, HDAC9a, HDAC9(ΔNLS), HDAC9a(ΔNLS), an HDRP(ΔNLS) polypeptides, and isolated nucleic acid molecules encoding those polypeptides. The present invention also features vectors containing HDAC9, HDAC9a, HDAC9(ΔNLS), HDAC9a(ΔNLS), and HDRP(ΔNLS) nucleic acid sequences, and cells containing those vectors.